Mary Spellman

1.6k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Mary Spellman is a scholar working on Dermatology, Immunology and Allergy and Immunology. According to data from OpenAlex, Mary Spellman has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Dermatology, 7 papers in Immunology and Allergy and 7 papers in Immunology. Recurrent topics in Mary Spellman's work include Dermatology and Skin Diseases (16 papers), Asthma and respiratory diseases (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Mary Spellman is often cited by papers focused on Dermatology and Skin Diseases (16 papers), Asthma and respiratory diseases (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Mary Spellman collaborates with scholars based in United States, Germany and Poland. Mary Spellman's co-authors include Mark Lebwohl, Alice B. Gottlieb, Robert S. Call, Linda Stein Gold, Lawrence F. Eichenfield, Adelaide A. Hebert, Lee T. Zane, Douglass W. Forsha, Mark Boguniewicz and Eric L. Simpson and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Mary Spellman

26 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

2016 415 citations Amy S. Paller, Wynnis L. Tom et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Spellman United States	15	777	514	308	244	205	28	1.2k
Ira D. Lawrence United States	13	410 0.5×	374 0.7×	260 0.8×	184 0.8×	140 0.7×	19	880
Faiz Ahmad United States	16	461 0.6×	236 0.5×	224 0.7×	242 1.0×	177 0.9×	25	958
Thomas Hultsch United States	22	1.6k 2.1×	1.6k 3.0×	413 1.3×	814 3.3×	283 1.4×	44	2.4k
Hanne Norsgaard Denmark	14	392 0.5×	116 0.2×	420 1.4×	133 0.5×	53 0.3×	23	661
E. Castela France	12	438 0.6×	80 0.2×	442 1.4×	51 0.2×	68 0.3×	14	860
Bark‐Lynn Lew South Korea	18	615 0.8×	125 0.2×	162 0.5×	90 0.4×	82 0.4×	89	1.1k
Lilla Landeck Germany	18	463 0.6×	194 0.4×	176 0.6×	53 0.2×	36 0.2×	42	728
Fareed Ahmad Qatar	17	264 0.3×	128 0.2×	224 0.7×	81 0.3×	81 0.4×	40	721
Emanuela Martina Italy	17	285 0.4×	48 0.1×	222 0.7×	189 0.8×	195 1.0×	49	770
M.D. Njoo Netherlands	17	843 1.1×	67 0.1×	661 2.1×	69 0.3×	74 0.4×	23	1.6k

Countries citing papers authored by Mary Spellman

Since Specialization

Citations

This map shows the geographic impact of Mary Spellman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Spellman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Spellman more than expected).

Fields of papers citing papers by Mary Spellman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Spellman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Spellman. The network helps show where Mary Spellman may publish in the future.

Co-authorship network of co-authors of Mary Spellman

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Spellman. A scholar is included among the top collaborators of Mary Spellman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Spellman. Mary Spellman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spellman, Mary, et al.. (2024). INTASYL PH-762: PD-1 intratumoral immunotherapy for cutaneous carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9620–TPS9620.

Zeidler, Claudia, Manuel P. Pereira, Matthias Augustin, Mary Spellman, & Sonja Ständer. (2020). Investigator’s Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials. Acta Dermato Venereologica. 101(2). adv00401–adv00401. 30 indexed citations

Pariser, David M., et al.. (2020). Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. Journal of the American Academy of Dermatology. 82(6). 1314–1320. 36 indexed citations

Ständer, Hartmut, Sarina B. Elmariah, Claudia Zeidler, Mary Spellman, & Sonja Ständer. (2019). Diagnostic and treatment algorithm for chronic nodular prurigo. Journal of the American Academy of Dermatology. 82(2). 460–468. 49 indexed citations

Eichenfield, Lawrence F., Robert S. Call, Douglass W. Forsha, et al.. (2017). Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology. 77(4). 641–649.e5. 109 indexed citations

Paller, Amy S., Wynnis L. Tom, Robert S. Call, et al.. (2016). 033 A novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor, Crisaborole Topical Ointment, 2%, in two phase 3 studies in children and adults with mild to moderate atopic dermatitis. Journal of Investigative Dermatology. 136(9). S166–S166. 3 indexed citations

Paller, Amy S., Wynnis L. Tom, Mark Lebwohl, et al.. (2016). Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology. 75(3). 494–503.e6. 415 indexed citations breakdown →

Eichenfield, Lawrence F., Robert S. Call, Douglass W. Forsha, et al.. (2016). 280 Long-term safety of crisaborole topical ointment, 2%, in atopic dermatitis. Journal of Investigative Dermatology. 136(5). S49–S49. 1 indexed citations

Zane, Lee T., Lawrence F. Eichenfield, Robert S. Call, et al.. (2016). Long-term safety of Crisaborole Topical Ointment, 2%, in children and adults with mild- to-moderate atopic dermatitis. The Journal of Immunology. 196(1_Supplement). 191.28–191.28. 3 indexed citations

10.

Paller, Amy S., Wynnis L. Tom, Mark Lebwohl, et al.. (2016). Two phase 3 studies in atopic dermatitis with crisaborole, the novel, nonsteroidal topical phosphodiesterase 4 inhibitor. 33. 2 indexed citations

11.

Cianciara, J, et al.. (2010). 300 PHASE 1B DOSE-ESCALATION STUDY OF SD-101, A NOVEL THERAPEUTIC TLR-9 AGONIST, IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology. 52. S126–S126. 3 indexed citations

12.

Poole, Jill A., Jianfeng Meng, Mitchell E. Reff, Mary Spellman, & Lanny J. Rosenwasser. (2005). Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. Journal of Allergy and Clinical Immunology. 116(4). 780–788. 61 indexed citations

13.

Gottlieb, Alice B., et al.. (2003). The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions. Journal of Cutaneous Medicine and Surgery. 7(3). 185–192. 54 indexed citations

14.

Franz, Thomas, Paul A. Lehman, Steven R. Feldman, & Mary Spellman. (2003). Bioavailability of Clobetasol Propionate in Different Vehicles. Skin Pharmacology and Physiology. 16(4). 212–216. 19 indexed citations

15.

Spellman, Mary. (2003). Self-assessment examination of the american academy of dermatology. Journal of the American Academy of Dermatology. 49(3). 561–566. 1 indexed citations

16.

Gottlieb, Alice B., James G. Krueger, Mark Ling, et al.. (2000). Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. Journal of the American Academy of Dermatology. 42(3). 428–435. 158 indexed citations

17.

Spellman, Mary, et al.. (1998). Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. Journal of the American Academy of Dermatology. 38(2). 318–321. 76 indexed citations

18.

Spellman, Mary & Stephanie H. Pincus. (1998). Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Clinical Therapeutics. 20(4). 711–721. 25 indexed citations

19.

Baird, Stephen M., Michael H. Weisman, Diane Amox, et al.. (1995). Oral 2‐chlorodeoxyadenosine in psoriatic. Arthritis & Rheumatism. 38(11). 1604–1609. 22 indexed citations

20.

Piacquadio, Daniel, et al.. (1994). Obesity and female androgenic alopecia: A cause and an effect?. Journal of the American Academy of Dermatology. 30(6). 1028–1030. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact